ConductScience.org, home

Comparison · NCT00514904-903a6c4a

Nimenrix Group vs Mencevax ACWY Group: Number of Subjects Reporting Any Serious Adverse Events (SAEs)

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Nimenrix Group vs Mencevax ACWY Group: Number of Subjects Reporting Any Serious Adverse Events (SAEs). Trial comparisons, record NCT00514904-903a6c4a. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00514904-903a6c4a

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.01330.00810.0219wilson
Risk in group 20.01860.009050.0379wilson
Risk difference, group 1 minus group 2-0.00528-0.02530.00755newcombe hybrid score
Risk ratio, group 1 over group 20.7160.2941.74log
Odds ratio, group 1 over group 20.7120.2881.76log
Number needed to treat, for one fewer participant with the outcome on Nimenrix Group than on Mencevax ACWY Group189from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Nimenrix GroupSubjects received 1 dose of Nimenrix vaccine at Month 0. Nimenrix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.151,125OG000
Group 2Mencevax ACWY GroupSubjects received 1 dose of Mencevax ACWY vaccine at Month 0. Mencevax ACWY vaccine was administered subcutaneously into the upper region of the non-dominant arm.7376OG001

Outcome

Type
SECONDARY
Title
Number of Subjects Reporting Any Serious Adverse Events (SAEs)
Description
SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability /incapacity or are a congenital anomaly/ birth defect in the offspring of a study subject.
Time frame
From Day 0 up to 6 months after vaccination
Population
The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom data were available.

Source ClinicalTrials.gov

Trial

Title
Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 2-10 Year Old Subjects
NCT number
NCT00514904
Phases
PHASE3
Conditions
Infections, Meningococcal, Meningococcal Vaccines
Interventions
Nimenrix, Mencevax
Lead sponsor
GlaxoSmithKline
Results first posted
2017-10-06

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00514904-903a6c4a